Atlas Trials

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

Clinical trial NCT05014139 · TERMINATED

Trial details

NCT number
NCT05014139
Sponsor
Astellas Pharma Global Development, Inc.
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Urinary Bladder NeoplasmsCarcinoma in SituCarcinoma Transitional CellNon-muscle Invasive Bladder CancerNMIBC
Start date
2021-12-07
Primary completion
2025-09-22
Enrollment
37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.